Bertold Renner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bertold Renner has a total of 352 co-authors. Here are the top co-authors by number of shared publications:
- Christian Albert Mueller
Department of Otorhinolaryngology, Head and Neck Surgery Medical University of Vienna Vienna Austria
29 shared publications - Gerold Besser
Department of Otorhinolaryngology, Head and Neck Surgery Medical University of Vienna Vienna Austria
18 shared publications - David Tianxiang Liu
Department of Otorhinolaryngology, Head and Neck Surgery Medical University of Vienna Vienna Austria
11 shared publications Gerd Kobal
10 shared publicationsKay Brune
Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nuremberg, Erlangen, Germany
10 shared publicationsChristian A. Mueller
Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria
7 shared publications
Latest Publications
- 24 September 2026
- Published by Georg Thieme Verlag KG in Suchttherapie
- Vol. 27 (S 01) , S67
Ergebnisse des Abwasserbasierten Begleitmonitorings im Rahmen der Einführung des Cannabisgesetzes in Deutschland
- 24 September 2026
- Published by Georg Thieme Verlag KG in Suchttherapie
- Vol. 27 (S 01) , S67
Ergebnisse des Abwasserbasierten Begleitmonitorings im Rahmen der Einführung des Cannabisgesetzes in Deutschland
- Open Access
- 3 June 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (11) , 1-16
Rapid quantification method of pharmaceuticals in urban wastewater using UHPLC-Orbitrap mass spectrometry—a multi-target approach for EU-directive advanced treatment evaluation
Pharmaceutical residues have become micropollutants of emerging concern in wastewater. Insufficient removal by wastewater treatment plants (WWTPs) can result in negative ecotoxicological impacts on aquatic ecosystems. Therefore, the EU Urban Wastewater Treatment Directive (UWWTD 2024/3019) requires quaternary treatment upgrades and regular monitoring in European wastewater treatment plants. This necessitates efficient and easy-to-implement wastewater analysis methods. Consequently, this study presents a novel, sensitive, and reliable HRMS-based method for the simultaneous determination of twelve indicator substances (nine UWWTD-listed and three substitutes) in WWTP influent and effluent. The method is based on solid-phase extraction (SPE) of 2 mL wastewater samples, followed by reversed-phase ultra-high performance liquid chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS) employing an Orbitrap Exploris™ 240. Detection was carried out using heated electrospray ionisation in positive ionisation mode (HESI+), except for diclofenac (HESI-). Quantification was performed using highly sensitive SIM scans, while high-resolution full-scan spectra were acquired for confirmation. Limits of quantification (LOQ) ranged mostly between 15 and 30 ng/L, except for candesartan, irbesartan, and diclofenac with LOQ > 50 ng/L. A laboratory validation demonstrated high precision and accuracy for all selected pharmaceuticals. Furthermore, the method was successfully applied to raw and treated wastewater from wastewater treatment plants (WWTPs) in the Saxon-Czech border region, which differ in terms of wastewater throughput and population equivalents. As a result, this method offers a rapid quantification approach for assessing the removal efficiency of pharmaceuticals and potential substitutes categorised in the UWWTD.
- 3 June 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (11) , 1-16
Open AccessRapid quantification method of pharmaceuticals in urban wastewater using UHPLC-Orbitrap mass spectrometry—a multi-target approach for EU-directive advanced treatment evaluation
Pharmaceutical residues have become micropollutants of emerging concern in wastewater. Insufficient removal by wastewater treatment plants (WWTPs) can result in negative ecotoxicological impacts on aquatic ecosystems. Therefore, the EU Urban Wastewater Treatment Directive (UWWTD 2024/3019) requires quaternary treatment upgrades and regular monitoring in European wastewater treatment plants. This necessitates efficient and easy-to-implement wastewater analysis methods. Consequently, this study presents a novel, sensitive, and reliable HRMS-based method for the simultaneous determination of twelve indicator substances (nine UWWTD-listed and three substitutes) in WWTP influent and effluent. The method is based on solid-phase extraction (SPE) of 2 mL wastewater samples, followed by reversed-phase ultra-high performance liquid chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS) employing an Orbitrap Exploris™ 240. Detection was carried out using heated electrospray ionisation in positive ionisation mode (HESI+), except for diclofenac (HESI-). Quantification was performed using highly sensitive SIM scans, while high-resolution full-scan spectra were acquired for confirmation. Limits of quantification (LOQ) ranged mostly between 15 and 30 ng/L, except for candesartan, irbesartan, and diclofenac with LOQ > 50 ng/L. A laboratory validation demonstrated high precision and accuracy for all selected pharmaceuticals. Furthermore, the method was successfully applied to raw and treated wastewater from wastewater treatment plants (WWTPs) in the Saxon-Czech border region, which differ in terms of wastewater throughput and population equivalents. As a result, this method offers a rapid quantification approach for assessing the removal efficiency of pharmaceuticals and potential substitutes categorised in the UWWTD.
- 24 February 2026
- Published by Springer Nature
- p. 429-454
Symptomatische Behandlung von Schmerz, Fieber und Entzündung
- 24 February 2026
- Published by Springer Nature
- p. 429-454
Symptomatische Behandlung von Schmerz, Fieber und Entzündung
- 24 February 2026
- Published by Springer Nature
- p. 469-476
Krankheitsmodifizierende Arzneistoffe für Autoimmunerkrankungen
- 24 February 2026
- Published by Springer Nature
- p. 469-476
Krankheitsmodifizierende Arzneistoffe für Autoimmunerkrankungen
- Open Access
- 16 December 2025
- Published by SAGE Publications in Annals of Otology, Rhinology & Laryngology
- Vol. 135 (4) , 305-312
Quality of Life and Chemosensory Function in Post-COVID Patients: Adherence to Olfactory Training
Objective: To evaluate adherence to and effects of standardized olfactory training (OT) after COVID-19 infection. Methods: In this prospective study, 475 patients (mean age 47.4/SD 9.5 years) with olfactory dysfunction (OD) after COVID-19 infection participated in OT on average 13 months (range 0-31 months) post-infection. Patients were assessed 3 times with an average interval of 3 months using questionnaires on quality of life (QoL), chemosensory functions, and OT adherence. Results: Overall, 363 patients (76.4%) took part in the first 2 and 49.1% in all 3 testing sessions. Before the initial assessment, 32.8% had performed OT in the past without any instructions, so that merely 9.1% adhered to recommended standards. By the second evaluation, after standardized OT was introduced to the participants, 31.1% (n = 106) reported following the training as recommended, decreasing to 18.5% (n = 43) by the third assessment, indicating that most participants did not complete the recommended duration of at least 12, preferably 24 to 36 weeks of olfactory training. QoL and subjective olfactory acuity significantly improved between the first and following testing sessions ( P < .001), but these improvements were not associated with adherence to OT. However, male sex ( P = .035), non-medical profession ( P = .025), increased age ( P = .009), and reduced QoL ( P = .027) were observed factors for advanced training adherence to recommended standards. Conclusion: Overall, only a small proportion of participants consistently followed OT. Higher adherence, however, was associated with male sex, non-medical profession, older age, and greater impairment in QoL. Nevertheless, on average there was a clear improvement in QoL and subjective sense of smell over the testing period.
- 16 December 2025
- Published by SAGE Publications in Annals of Otology, Rhinology & Laryngology
- Vol. 135 (4) , 305-312
Open AccessQuality of Life and Chemosensory Function in Post-COVID Patients: Adherence to Olfactory Training
Objective: To evaluate adherence to and effects of standardized olfactory training (OT) after COVID-19 infection. Methods: In this prospective study, 475 patients (mean age 47.4/SD 9.5 years) with olfactory dysfunction (OD) after COVID-19 infection participated in OT on average 13 months (range 0-31 months) post-infection. Patients were assessed 3 times with an average interval of 3 months using questionnaires on quality of life (QoL), chemosensory functions, and OT adherence. Results: Overall, 363 patients (76.4%) took part in the first 2 and 49.1% in all 3 testing sessions. Before the initial assessment, 32.8% had performed OT in the past without any instructions, so that merely 9.1% adhered to recommended standards. By the second evaluation, after standardized OT was introduced to the participants, 31.1% (n = 106) reported following the training as recommended, decreasing to 18.5% (n = 43) by the third assessment, indicating that most participants did not complete the recommended duration of at least 12, preferably 24 to 36 weeks of olfactory training. QoL and subjective olfactory acuity significantly improved between the first and following testing sessions ( P < .001), but these improvements were not associated with adherence to OT. However, male sex ( P = .035), non-medical profession ( P = .025), increased age ( P = .009), and reduced QoL ( P = .027) were observed factors for advanced training adherence to recommended standards. Conclusion: Overall, only a small proportion of participants consistently followed OT. Higher adherence, however, was associated with male sex, non-medical profession, older age, and greater impairment in QoL. Nevertheless, on average there was a clear improvement in QoL and subjective sense of smell over the testing period.
- Open Access
The Pharmacokinetics, Dosage, Preparation Forms, and Efficacy of Orally Administered Melatonin for Non-Organic Sleep Disorders in Autism Spectrum Disorder During Childhood and Adolescence: A Systematic Review
Background: To date, it remains unclear which oral doses and preparation forms of melatonin should be recommended for children and adolescents with non-organic sleep disorders and autism spectrum disorder (ASD). We reviewed the current state of knowledge on this topic based on randomised placebo-controlled trials (RCTs) and diagnosis-related blood melatonin concentrations available in this age group. Method: Two investigators independently searched PubMed, PsycINFO, MEDLINE, and Cochrane CENTRAL on 1 March 2025 for the keywords “melatonin”, “autism”, and “randomised” in titles and abstracts in all languages, including an evaluation of the references of the reviews, systematic reviews, and meta-analyses published up to that date, some of which were based on searches in numerous databases. Based on this, additional in-depth searches were carried out in PubMed for pharmacokinetic, physiological, and pathophysiological data on melatonin in children and adolescents, with a special focus on ASD. Results: To date, five RCTs on non-organic sleep disorders in children and adolescents with the sole diagnosis of ASD or with subgroup analyses in the presence of several initial diagnoses such as ADHD, epilepsy, Smith–Magenis, or Fragile X syndrome are available. In these studies, rapid-release, non-delayed preparations were administered orally. In one of these studies, the clinical efficacy of a combination preparation with a sustained-release and a non-released active substance component was tested. Pharmacokinetic data with multiple determinations of melatonin concentrations in the blood are only available for children with ASD in the form of a case series (N = 9). Discussion: RCTs comparing the efficacy of delayed melatonin preparations with non-delayed rapid-release oral preparations are not yet available. Physiological data and clinical effects documented in five RCTs indicate that non-delayed melatonin preparations with an initial rapid onset of action are effective for non-organic sleep disorders in children and adolescents with ASD. Conclusions: From a clinical, pharmacokinetic, and physiological point of view, the RCTs available to date and the data on melatonin concentrations in the blood of children with ASD, measured several times over 24 h, suggest that a low oral melatonin dose and a non-delayed preparation with rapid onset should be started in children and adolescents with non-organic sleep disorders in ASD, if sleep hygiene advice and psychotherapeutic interventions have not demonstrated sufficient effects.
Open AccessThe Pharmacokinetics, Dosage, Preparation Forms, and Efficacy of Orally Administered Melatonin for Non-Organic Sleep Disorders in Autism Spectrum Disorder During Childhood and Adolescence: A Systematic Review
Background: To date, it remains unclear which oral doses and preparation forms of melatonin should be recommended for children and adolescents with non-organic sleep disorders and autism spectrum disorder (ASD). We reviewed the current state of knowledge on this topic based on randomised placebo-controlled trials (RCTs) and diagnosis-related blood melatonin concentrations available in this age group. Method: Two investigators independently searched PubMed, PsycINFO, MEDLINE, and Cochrane CENTRAL on 1 March 2025 for the keywords “melatonin”, “autism”, and “randomised” in titles and abstracts in all languages, including an evaluation of the references of the reviews, systematic reviews, and meta-analyses published up to that date, some of which were based on searches in numerous databases. Based on this, additional in-depth searches were carried out in PubMed for pharmacokinetic, physiological, and pathophysiological data on melatonin in children and adolescents, with a special focus on ASD. Results: To date, five RCTs on non-organic sleep disorders in children and adolescents with the sole diagnosis of ASD or with subgroup analyses in the presence of several initial diagnoses such as ADHD, epilepsy, Smith–Magenis, or Fragile X syndrome are available. In these studies, rapid-release, non-delayed preparations were administered orally. In one of these studies, the clinical efficacy of a combination preparation with a sustained-release and a non-released active substance component was tested. Pharmacokinetic data with multiple determinations of melatonin concentrations in the blood are only available for children with ASD in the form of a case series (N = 9). Discussion: RCTs comparing the efficacy of delayed melatonin preparations with non-delayed rapid-release oral preparations are not yet available. Physiological data and clinical effects documented in five RCTs indicate that non-delayed melatonin preparations with an initial rapid onset of action are effective for non-organic sleep disorders in children and adolescents with ASD. Conclusions: From a clinical, pharmacokinetic, and physiological point of view, the RCTs available to date and the data on melatonin concentrations in the blood of children with ASD, measured several times over 24 h, suggest that a low oral melatonin dose and a non-delayed preparation with rapid onset should be started in children and adolescents with non-organic sleep disorders in ASD, if sleep hygiene advice and psychotherapeutic interventions have not demonstrated sufficient effects.
- Open Access
- 17 February 2025
- Published by Springer Nature in Journal of Public Health
- Vol. 34 (9) , 1-11
Effects of the introduction of biosimilars on the costs and prescription frequency of selected biologics in statutory and private health insurance in Germany: differences and similarities
Aim: Biologicals are jointly responsible for growing healthcare expenditures due to their innovation, patent protection, and the increasing number of indications they are used for. The aim of the study was to investigate how costs and prescription volumes of several biologicals developed in a collective of insured persons in statutory health insurance (SHI) and private health insurance (PHI) in Germany over a period from 2016 to 2020. Subject and methods: Primary outpatient prescription data of pharmaceuticals from an SHI and a PHI collective was used focusing on the monoclonal antibodies adalimumab, infliximab, rituximab, and trastuzumab, as well as the differences between their reference drugs and biosimilars. Results: Total prescription volumes of the anti-rheumatic drugs increased while those of the oncologicals decreased. Prescriptions for reference drugs fell in all cases, particularly after the market launch of the first biosimilars. However, while the decline in prescriptions of adalimumab and infliximab in PHI occurred later and more slowly than in SHI, the trend for rituximab and trastuzumab was almost parallel in both systems. In most cases, costs developed in line with prescriptions. Market competition and statutory control mechanisms had a positive impact on overall costs. Conclusion: Statutory control mechanisms such as prescription target quotas and reference price groups in SHI are effective for the drugs investigated. Nevertheless, biosimilar rates in SHI and PHI are not as far apart as the generics rate. For more expensive active substances, a switch to the cheaper biosimilars is more likely than for comparatively cheaper drugs.
- 17 February 2025
- Published by Springer Nature in Journal of Public Health
- Vol. 34 (9) , 1-11
Open AccessEffects of the introduction of biosimilars on the costs and prescription frequency of selected biologics in statutory and private health insurance in Germany: differences and similarities
Aim: Biologicals are jointly responsible for growing healthcare expenditures due to their innovation, patent protection, and the increasing number of indications they are used for. The aim of the study was to investigate how costs and prescription volumes of several biologicals developed in a collective of insured persons in statutory health insurance (SHI) and private health insurance (PHI) in Germany over a period from 2016 to 2020. Subject and methods: Primary outpatient prescription data of pharmaceuticals from an SHI and a PHI collective was used focusing on the monoclonal antibodies adalimumab, infliximab, rituximab, and trastuzumab, as well as the differences between their reference drugs and biosimilars. Results: Total prescription volumes of the anti-rheumatic drugs increased while those of the oncologicals decreased. Prescriptions for reference drugs fell in all cases, particularly after the market launch of the first biosimilars. However, while the decline in prescriptions of adalimumab and infliximab in PHI occurred later and more slowly than in SHI, the trend for rituximab and trastuzumab was almost parallel in both systems. In most cases, costs developed in line with prescriptions. Market competition and statutory control mechanisms had a positive impact on overall costs. Conclusion: Statutory control mechanisms such as prescription target quotas and reference price groups in SHI are effective for the drugs investigated. Nevertheless, biosimilar rates in SHI and PHI are not as far apart as the generics rate. For more expensive active substances, a switch to the cheaper biosimilars is more likely than for comparatively cheaper drugs.
- Open Access
- 30 October 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-17
Radiation-induced morphea of the breast – characterization and treatment of fibroblast dysfunction with repurposed mesalazine
Radiation-induced morphea (RIM) is a rare complication of radiotherapy presenting as inflammatory fibrosis, most commonly reported in breast cancer patients. As underlying disease mechanisms are not well understood, targeted therapies are lacking. Since fibroblasts are the key mediators of all fibroproliferative diseases, this study aimed to characterize patient-derived fibroblasts to identify therapeutic targets. We studied primary human control and RIM-fibroblasts on a functional and molecular basis, analyzed peripheral blood and tissue samples and conducted, based on our findings, a treatment attempt in one patient. In RIM, we identified a distinct myofibroblast phenotype reflected by increased alpha-smooth-muscle-actin (αSMA) expression, reduced proliferation and migration rates, and overexpression of osteopontin (OPN). Our RNA sequencing identified aberrant Myc activation as a potential disease driver in RIM fibroblasts, similar to previous findings in systemic sclerosis. Treatment with the anti-inflammatory drug mesalazine reversed the myofibroblast phenotype by targeting Myc. Based on these findings, a patient with RIM was successfully treated with mesalazine, resulting in reduced inflammation and pain and tissue softening, while serum OPN was halved. The present study provides a comprehensive characterization of RIM fibroblasts, suggests a disease-driving role for Myc, demonstrates promising antifibrotic effects of mesalazine and proposes OPN as a biomarker for RIM.
- 30 October 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-17
Open AccessRadiation-induced morphea of the breast – characterization and treatment of fibroblast dysfunction with repurposed mesalazine
Radiation-induced morphea (RIM) is a rare complication of radiotherapy presenting as inflammatory fibrosis, most commonly reported in breast cancer patients. As underlying disease mechanisms are not well understood, targeted therapies are lacking. Since fibroblasts are the key mediators of all fibroproliferative diseases, this study aimed to characterize patient-derived fibroblasts to identify therapeutic targets. We studied primary human control and RIM-fibroblasts on a functional and molecular basis, analyzed peripheral blood and tissue samples and conducted, based on our findings, a treatment attempt in one patient. In RIM, we identified a distinct myofibroblast phenotype reflected by increased alpha-smooth-muscle-actin (αSMA) expression, reduced proliferation and migration rates, and overexpression of osteopontin (OPN). Our RNA sequencing identified aberrant Myc activation as a potential disease driver in RIM fibroblasts, similar to previous findings in systemic sclerosis. Treatment with the anti-inflammatory drug mesalazine reversed the myofibroblast phenotype by targeting Myc. Based on these findings, a patient with RIM was successfully treated with mesalazine, resulting in reduced inflammation and pain and tissue softening, while serum OPN was halved. The present study provides a comprehensive characterization of RIM fibroblasts, suggests a disease-driving role for Myc, demonstrates promising antifibrotic effects of mesalazine and proposes OPN as a biomarker for RIM.
- Open Access
- 21 September 2024
- Published by Wiley in Clinical Otolaryngology
- Vol. 50 (1) , 53-61
Factors Associated With Persisting Olfactory Dysfunction After COVID‐19
Background: Fortunately, the majority of COVID‐19 patients recover from olfactory dysfunction (OD) within the first couple of weeks. However, from approximately 5% up to 20% continue to suffer from OD even more than 1 year after the onset. Nonetheless, factors associated with long‐lasting OD are hardly known. The aim of this study was to identify favourable and disadvantageous markers of persisting OD in COVID‐19 patients.Methodology: Sixty‐six patients (46 female; mean age: 39.9 years) that suffer from OD longer than 6 months due to laboratory‐confirmed SARS‐CoV‐2 infection have participated in this longitudinal study. Participants completed comprehensive psychophysical chemosensory tests (i.e., Sniffin' Sticks = TDI) and questionnaires twice at our department—on average 219 ± 80 (T‐1) and 489 ± 89 (T‐2) days after the onset of symptoms, respectively. Olfactory recovery rates were associated with demographic factors and questionnaires using linear regression analysis.Results: Patients below 40 years of age improved better (TDI: 4.1 ± 4.3 vs. 0.7 ± 5.8; p = 0.008) and achieved statistically significant higher scores (TDI: 31.5 ± 4.0 vs. 27.3 ± 6.7; p = 0.033) regarding psychophysical chemosensory tests. Furthermore, linear regression analysis revealed that parosmia was associated with worse orthonasal smell function (T‐1: β = −0.346, p = 0.004; T‐2: β = −0.384, p = 0.001), especially concerning identification subtest (T‐1: β = −0.395, p = 0.001; T‐2: β = −0.398, p < 0.001). Moreover, increasing parosmia between T‐1and T‐2 led to worse orthonasal olfactory function (β = −0.294, p = 0.016).Conclusions: Older age and parosmia seem to be unfavourable factors of persisting OD in COVID‐19 patients.
- 21 September 2024
- Published by Wiley in Clinical Otolaryngology
- Vol. 50 (1) , 53-61
Open AccessFactors Associated With Persisting Olfactory Dysfunction After COVID‐19
Background: Fortunately, the majority of COVID‐19 patients recover from olfactory dysfunction (OD) within the first couple of weeks. However, from approximately 5% up to 20% continue to suffer from OD even more than 1 year after the onset. Nonetheless, factors associated with long‐lasting OD are hardly known. The aim of this study was to identify favourable and disadvantageous markers of persisting OD in COVID‐19 patients.Methodology: Sixty‐six patients (46 female; mean age: 39.9 years) that suffer from OD longer than 6 months due to laboratory‐confirmed SARS‐CoV‐2 infection have participated in this longitudinal study. Participants completed comprehensive psychophysical chemosensory tests (i.e., Sniffin' Sticks = TDI) and questionnaires twice at our department—on average 219 ± 80 (T‐1) and 489 ± 89 (T‐2) days after the onset of symptoms, respectively. Olfactory recovery rates were associated with demographic factors and questionnaires using linear regression analysis.Results: Patients below 40 years of age improved better (TDI: 4.1 ± 4.3 vs. 0.7 ± 5.8; p = 0.008) and achieved statistically significant higher scores (TDI: 31.5 ± 4.0 vs. 27.3 ± 6.7; p = 0.033) regarding psychophysical chemosensory tests. Furthermore, linear regression analysis revealed that parosmia was associated with worse orthonasal smell function (T‐1: β = −0.346, p = 0.004; T‐2: β = −0.384, p = 0.001), especially concerning identification subtest (T‐1: β = −0.395, p = 0.001; T‐2: β = −0.398, p < 0.001). Moreover, increasing parosmia between T‐1and T‐2 led to worse orthonasal olfactory function (β = −0.294, p = 0.016).Conclusions: Older age and parosmia seem to be unfavourable factors of persisting OD in COVID‐19 patients.